World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
56
Citations
15078
World Ranking
3667
National Ranking
1439

Hongmei Mo publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Hongmei Mo sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 188 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Hongmei Mo D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Hongmei Mo sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 56 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Hongmei Mo is affiliated with Gilead Sciences in the United States and has a research focus centered on infectious diseases, particularly viral infections affecting the liver and respiratory system. Their body of work spans several crucial areas within medicine, with a notable emphasis on hepatitis viruses and SARS-CoV-2.

The scientist's main fields of study include:

  • Medicine

Within their medical research, key subfields are:

  • Epidemiology
  • Hepatology
  • Infectious Diseases
  • Molecular Biology
  • Surgery

The following topics represent primary focuses of their research:

  • Hepatitis B Virus Studies
  • Hepatitis C Virus Research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis Viruses Studies and Epidemiology
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Viral Infections and Immunology Research

Hongmei Mo has contributed to multiple peer-reviewed scientific journals, with frequent publications in:

  • Journal of Hepatology
  • JHEP Reports
  • Journal of Viral Hepatitis
  • Journal of Virology
  • bioRxiv (Cold Spring Harbor Laboratory)

Several recent papers illustrate the scope and thematic interests of their research:

  • "Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants" (2022, Antimicrobial Agents and Chemotherapy)
  • "Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir" (2021, Antiviral Research)
  • "Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection" (2021, JHEP Reports)
  • "Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B" (2022, JHEP Reports)
  • "Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines" (2021, Journal of Virology)

Collaboration has been a notable aspect of Hongmei Mo's work, frequently partnering with other researchers such as Ross Martin, Savrina Manhas, Becket Feierbach, Lindsey May, and Yang Liu. These collaborations reflect a multidisciplinary approach connecting epidemiology, molecular biology, and clinical research perspectives.

Best Publications

  • Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

    Nezam Afdhal;Stefan Zeuzem;Paul Kwo;Mario Chojkier

  • Genotypic and phenotypic characterization of HIV-1 patients with primary infection

    Tuofu Zhu;Hongmei Mo;Ning Wang;Daniel S. Nam

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

    Eric Lawitz;Fred F Poordad;Phillip S Pang;Robert H Hyland

  • Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

    Masashi Mizokami;Osamu Yokosuka;Tetsuo Takehara;Naoya Sakamoto

  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

    Eric Lawitz;Jay P Lalezari;Tarek Hassanein;Kris V Kowdley

  • Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

    Sergio M Borgia;Charlotte Hedskog;Bandita Parhy;Robert H Hyland

  • Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Erik Lontok;Patrick Harrington;Anita Howe;Tara Kieffer

  • Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

    M. Markowitz;Hongmei Mo;D. J. Kempf;D. W. Norbeck

  • Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

    Christoph Sarrazin;Hadas Dvory-Sobol;Evguenia S. Svarovskaia;Brian P. Doehle

  • Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

    Liangjun Lu;Tami J. Pilot-Matias;Kent D. Stewart;John T. Randolph

  • Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

    Evguenia S. Svarovskaia;Hadas Dvory-Sobol;Neil Parkin;Christy Hebner

  • NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

    Stefan Zeuzem;Masashi Mizokami;Stephen Pianko;Alessandra Mangia

  • A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

    Eric J. Lawitz;Daniel Gruener;John M. Hill;Thomas Marbury

  • Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

    Unknown

  • Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

    Teresa I. Ng;Hongmei Mo;Tami Pilot-Matias;Yupeng He

  • Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

    Megan H. Powdrill;Egor P. Tchesnokov;Robert A. Kozak;Rodney S. Russell

  • Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

    Hongmei Mo;Liangjun Lu;Tami Pilot-Matias;Ron Pithawalla

  • Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses

    Tania M. Welzel;Neeru Bhardwaj;Charlotte Hedskog;Krishna Chodavarapu

  • The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

    Stefan Zeuzem;Peter Buggisch;Kosh Agarwal;Patrick Marcellin

  • Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.

    Christoph Sarrazin;Vasily Isakov;Evguenia S. Svarovskaia;Charlotte Hedskog

  • Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

    Christophe Hezode;Nancy Reau;Evguenia S. Svarovskaia;Brian P. Doehle

Frequent Co-Authors

Michael D. Miller
Michael D. Miller United States Military Academy
John G. McHutchison
John G. McHutchison Duke University
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Tami Pilot-Matias
Tami Pilot-Matias AbbVie (United States)
Ira M. Jacobson
Ira M. Jacobson New York University
Adrian S. Ray
Adrian S. Ray Yale University
Jacques Fellay
Jacques Fellay École Polytechnique Fédérale de Lausanne
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens the door to various specialized career paths beyond traditional laboratory roles. For those interested in healthcare administration and data management, pursuing accredited programs can be a strategic move. One promising avenue is to explore the certified professional coder (cpc) track, which focuses on medical coding and billing, essential for accurate healthcare documentation and reimbursement processes.

Many professionals combine microbiology knowledge with healthcare information skills, benefitting from higher salaries in leadership roles. The role of a health information manager is particularly noteworthy, with competitive pay and a critical place in health data oversight. To further this career, it’s beneficial to look into the best online cahiim accredited health information management degree programs, which provide recognized credentials that meet industry standards.

For quicker entry into the field, enrolling in an accredited fast medical billing and coding certificate online program can jumpstart your career with practical skills and certification. These programs cater to busy students and professionals looking to transition or upskill efficiently.

Ultimately, combining microbiology expertise with credentialed programs in health information and coding allows graduates to pursue diverse and lucrative career pathways across healthcare and biomedical sectors.

Best Scientists Citing Hongmei Mo

Trending Scientists

Recently Published Articles